


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-63. (Cancelled)

Claim 64. (Currently Amended) A compound having the structure:



wherein R₁ is independently H, F, Cl, Br, -CN, -OH, -NO₂, -NR₅R₆, -SO₂R₅, - (CH₂)_nOR₅, - (CH₂)_nCONR₅R₆, - (CH₂)_nNR₅COR₅, perfluoroalkyl, polyfluoroalkyl, aminoalkyl, or straight chained or branched C₁-C₇ alkyl;


wherein R₅ is independently H; or straight chained or branched C₁-C₇ alkyl;

wherein R₆ is independently H; or straight chained or branched C₁-C₇ alkyl;

wherein each n independently is an integer from 0 to 6 inclusive;

wherein R₇ is independently straight chained or branched C₁-C₇ alkyl;


wherein R₈ is



wherein R₉ is independently H; or straight chained or branched C₁-C₄ alkyl;

wherein R₁₀ is independently H; or straight chained or branched C₁-C₄ alkyl;

wherein R₁₁ is



wherein R₁₂ is H, straight chained or branched C₁-C₇ alkyl, $-(\text{CH}_2)_u\text{OR}_{17}$, or $-\text{O}(\text{CH}_2)_u\text{OR}_{17}$;

wherein R₁₃ is independently H; $-(\text{CH}_2)_u\text{OR}_5$; $-(\text{CH}_2)_t\text{CONR}_5\text{R}_6$; $-(\text{CH}_2)_u\text{NR}_5\text{COR}_5$; $-(\text{CH}_2)_t\text{COR}_7$; $-(\text{CH}_2)_t\text{CO}_2\text{R}_5$; $-(\text{CH}_2)_u\text{NR}_5\text{R}_6$; $-(\text{CH}_2)_u\text{CN}$; straight chained or branched C₁-C₇ alkyl; C₁-C₇ alkyl in which the C₂-C₇ atoms may be optionally substituted with one or more F or Cl; C₃-C₇ cycloalkyl-C₁-C₇ alkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; or C₃-C₇ cycloalkyl; phenyl or C₁-C₆ phenylalkyl; wherein the phenyl or C₁-C₆ phenylalkyl may be substituted with one or more of F, Cl, -CN, -NO₂, -NR₅R₆, -SO₂R₅, $-(\text{CH}_2)_n\text{COR}_7$, $-(\text{CH}_2)_n\text{OR}_5$, $-(\text{CH}_2)_n\text{CONR}_5\text{R}_6$, $-(\text{CH}_2)_n\text{NR}_5\text{COR}_5$, $-(\text{CH}_2)_n\text{CO}_2\text{R}_5$, $-(\text{CH}_2)_n\text{SO}_2\text{NR}_5\text{R}_6$, straight chained or branched C₁-C₇ alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl;

or R₁₂ and R₁₃ together with the amide linkage to which they are attached are pyrrolidinonyl, piperidinonyl or oxazolidinonyl;


wherein R_{14} is H; straight chained or branched C_1 - C_4 alkyl; F; or $-(CH_2)_rOR_5$;

wherein R_{15} is H, straight chained or branched C_1 - C_4 alkyl, or F; with the proviso that when R_{14} is $-OH$, R_{15} cannot be F;

wherein R_{16} is perfluoroalkyl, unsubstituted straight chained or branched C_1 - C_7 alkyl, substituted straight chained or branched C_2 - C_7 alkyl, wherein the C_2 - C_7 alkyl may be substituted with one or more of F, Cl, $-CN$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nOCF_3$, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl, straight chained or branched C_2 - C_7 alkenyl or alkynyl, or C_3 - C_7 cycloalkyl or cycloalkenyl; phenyl, heteroaryl, or C_1 - C_7 phenylalkyl, wherein the phenyl, heteroaryl, or C_1 - C_7 phenylalkyl may be substituted with one or more of F, Cl, Br, $-CN$, $-NO_2$, $-NR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nSO_2NR_5R_6$, ethylenedioxy, methylenedioxy, straight chained or branched C_1 - C_7 alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl, straight chained or branched C_2 - C_7 alkenyl or alkynyl, or C_3 - C_7 cycloalkyl or cycloalkenyl; quinolinyl, 1-naphthyl, 2-naphthyl, or 2,1,3-benzothiadiazolyl; wherein the quinolinyl, 1-naphthyl, 2-naphthyl, or 2,1,3-benzothiadiazolyl may be substituted with one or more of F, Cl, Br, $-CN$, $-NO_2$, $-NR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nSO_2NR_5R_6$, ethylenedioxy, methylenedioxy, straight chained or branched C_1 - C_7 alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl;

with the proviso that when R_8 is $NR_9(R_{14}R_{15})NR_{10}R_{11}$, R_{16} cannot be quinolinyl;

with the proviso that when R_8 is



R_{16} cannot be quinolinyl;

wherein R_{17} is H, straight chained or branched C_1 - C_4 alkyl, perfluoroalkyl, or polyfluoroalkyl;

wherein each p independently is an integer from 0 to 2 inclusive;

wherein each r independently is an integer from 0 to 3 inclusive;

wherein each s independently is an integer from 1 to 6 inclusive;

wherein t is an integer from 1 to 4 inclusive; and


wherein each u independently is an integer from 2 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.


Claim 65. (Previously Presented) The compound of claim 64, wherein R_1 is independently H, F, Cl or Br;

wherein R_{16} is unsubstituted straight chained or branched C_1 - C_7 alkyl, phenyl, heteroaryl, or C_1 - C_7 phenylalkyl, wherein the phenyl, heteroaryl, or C_1 - C_7 phenylalkyl may be substituted with one or more of F, Cl, Br, -CN, -NO₂, -NR₅R₆, - (CH₂)_nNR₅COR₅, -SO₂R₅, - (CH₂)_nCOR₇, - (CH₂)_nOR₅, - (CH₂)_nCONR₅R₆, - (CH₂)_nCO₂R₅ and - (CH₂)_nSO₂NR₅R₆; and p is 1.


Claim 66. (Previously Presented) The compound of claim 65, wherein R_8 is




Claim 67. (Previously Presented) The compound of claim 66, wherein the compound is




Claim 68. (Previously Presented) The compound of claim 65, wherein R_8 is




Claim 69. (Previously Presented) The compound of claim 68, wherein the compound is selected from the group consisting of:



Claim 70. (Previously Presented) The compound of claim 65, wherein R_8 is



Claim 71. (Previously Presented) The compound of claim 70, wherein the compound is selected from the group consisting of:



Claim 72. (Previously Presented) The compound of claim 64, wherein the compound is the (+) enantiomer.

Claim 73. (Previously Presented) The compound of claim 64, wherein the compound is the (-) enantiomer.

Claim 74. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

Claim 75. (Previously Presented) The pharmaceutical composition of claim 64, wherein the amount of the compound is an amount from about 0.01mg to about 800mg.

Claim 76. (Previously Presented) The pharmaceutical composition of claim 75, wherein the amount of the compound is an amount from about 0.01mg to about 500mg.

Claim 77. (Previously Presented) The pharmaceutical composition of claim 76, wherein the amount of the compound is an amount from about 0.01mg to about 250mg.

Claim 78. (Previously Presented) The pharmaceutical composition of claim 77, wherein the amount of the compound is an amount from about 0.1mg to about 60mg.

Claim 79. (Previously Presented) The pharmaceutical composition of claim 78, wherein the amount of the compound is an amount from about 1mg to about 20mg.

Claim 80. (Previously Presented) The pharmaceutical composition of claim 74, wherein the carrier is a liquid and the composition is a solution.

Claim 81. (Previously Presented) The pharmaceutical composition of claim 74, wherein the carrier is a solid and the composition is a tablet.


Claim 82. (Previously Presented) The pharmaceutical composition of claim 74, wherein the carrier is a gel and the composition is a suppository.

Claim 83. (Previously Presented) A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

Claim 84. (Previously Presented) A process for making a pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

Claims 85-88. (Cancelled)

Claim 89. (Previously Presented) The compound of claim 71, wherein the compound has the structure:



Claim 90. (Previously Presented) A method of treating a subject suffering from an eating disorder, which comprises administering to the subject a therapeutically effective amount of the compound of claim 64 to treat the subject's eating disorder.

Claim 91. (Previously Presented) A method of treating a subject suffering from an eating disorder, which comprises administering to the subject a therapeutically effective amount of the compound of claim 89 to treat the subject's eating disorder.

Claim 92. (Previously Presented) A method of treating a subject suffering from obesity, which comprises administering to the subject a therapeutically effective amount of the compound of claim 64 to treat the subject's obesity.

Claim 93. (Previously Presented) A method of treating a subject suffering from obesity, which comprises administering to the subject a therapeutically effective amount of the compound of claim 89 to treat the subject's obesity.

Claim 94. (Previously Presented) A method of treating a subject suffering from depression, which comprises administering to the subject a therapeutically effective amount of the compound of claim 64 to treat the subject's depression.

Claim 95. (Previously Presented) A method of treating a subject suffering from depression, which comprises administering to the subject a therapeutically effective amount of the compound of claim 89 to treat the subject's depression.

Claim 96. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 89 and a pharmaceutically acceptable carrier.